A proven approved drug with PEG of high growth rate of 0.3 and p/e of 8.2. .Positive cash flow, no debt but cash on book. Sales are increasing and applying variation of drug to other applicable areas. It will be an accredit purchase and built synergy in distribution. Other pharm. may preempt the purchase.